DALLAS--(BUSINESS WIRE)--
Lantern Pharma, Inc. (Dallas, TX, US) and BioNumerik Pharmaceuticals,
Inc. of San Antonio, Texas have entered into an exclusive agreement for
Lantern Pharma to evaluate BioNumerik’s Tavocept® for human
therapeutic indications using Lantern’s 5-M theranostic platform.
Tavocept is an investigational new drug candidate from BioNumerik’s
portfolio that has shown potential for both oncology and non-oncology
indications. Lantern Pharma is a Precision Oncology Medicine company
focused on using its proprietary 5-M platform to identify specific drug
sensitivity signatures for patient tumor types. The Tavocept transaction
demonstrates Lantern’s commitment to the development of precision cancer
drugs by employing its cutting-edge companion 5-M theranostics platform
with the objective of providing more precise and therefore more
effective treatments to patients sooner.
Dr. Arun Asaithambi of Lantern Pharma, commented: "We believe
Lantern Pharma’s approach can be successfully applied to identify new
value opportunities for drug candidates with promising potential that
have encountered development challenges. We are excited about Tavocept
and the potential to enhance its therapeutic potency through the
application of our 5-M approach.”
“We believe Tavocept has important potential to be of benefit to
patients, and we are excited to be working with Lantern Pharma to
examine possible ways to realize and expand that potential,” said Thomas
W. Lyles, Jr., President of BioNumerik Pharmaceuticals, Inc.
About Lantern Pharma:
Lantern Pharma is leading a wave of innovation in cancer treatment aimed
at bringing the best therapies to patients who are most likely to
respond. Lantern Pharma is pioneering a precision medicine approach to
cancer by tailoring promising drug programs to the right patients.
Lantern Pharma has three investigational drug candidates at the clinical
and pre-clinical stage. The company’s proprietary 5-M Theranostic
platform uses biomarker based molecular genetic screening to identify
tumor specific drug sensitivity signatures to help identify those drugs
that are most likely to have enhanced potency for a particular patient’s
tumor, thereby facilitating the ability to more quickly treat those
patients who are likely to benefit most from the identified treatment.
About BioNumerik:
BioNumerik Pharmaceuticals, Inc. is focused on the development and
commercialization of novel drugs for the treatment of cancer and cancer
supportive care. BioNumerik currently has two investigational drug
candidates at the clinical development stage.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160805005811/en/
Lantern Pharma, Inc.
Arun Asaithambi, 469-751-7960
info@lanternpharma.com
or
BioNumerik
Pharmaceuticals, Inc.
info@bnpi.com
Source: Lantern Pharma, Inc.
Released August 5, 2016